Entry to sleep drugs is a worldwide drawback, with about 80% of individuals with sleep apnea remaining undiagnosed. A number of startups are utilizing AI to try to deal with this situation — and on Wednesday, one in all these firms introduced that it had raised $20 million to advance its suite of sleep expertise.
Madison, Wisconsin-based EnsoData’s Sequence B funding spherical was led by Questa Capital. The spherical takes the corporate’s whole funding to this point to “simply over” $50 million, in keeping with CEO Justin Mortara.
EnsoData, based in 2015, makes use of AI to research sleep research knowledge from polysomnography research or house sleep apnea assessments. The platform research sufferers’ sleep levels and respiratory occasions to rapidly detect occasions like apneas, hypopneas and arousals.
This expertise, which integrates into suppliers’ current workflows, helps clinicians diagnose sleep issues sooner and extra constantly, Mortara defined.
“EnsoData’s expertise saves clinicians time and permits personal sleep labs and healthcare methods to offer sufferers with quick and correct diagnoses, remedy and outcomes — whereas additionally producing extra income by lowering the period of time clinicians spend analyzing knowledge by practically 70%,” he declared.
Historically, sleep technicians overview sleep research manually, which might take a pair hours per research and might differ by scorer. EnsoData’s AI platform automates this course of and generates sleep stories inside minutes, permitting clinicians to spend much less time scoring and extra time decoding outcomes and caring for sufferers.
Working on a SaaS enterprise mannequin, EnsoData expenses on a per affected person foundation, slightly than a per take a look at foundation like most system producers in sleep drugs, Mortara said.
He mentioned that his firm has quite a lot of rivals within the sleep apnea diagnostic house — all of that are primarily {hardware} builders slightly than software program options, together with firms like Zoll and SleepImage.
EnsoData differentiates itself by promoting software program as a medical gadgets (SaMDs), he identified.
“The FDA cleared options are appropriate with all main gadgets, that means interoperability is a transparent differentiator,” Mortara remarked.
EnsoData’s SaaS mannequin can be extra scalable, as the corporate expenses beneath $25 per affected person, he added.
Throughout all its options, EnsoData serves greater than 125 clients and is supporting greater than 75,000 sufferers every month. Its goal clients are suppliers within the sleep drugs house, notably sleep facilities inside well being methods, personal sleep clinics, sleep administration organizations and unbiased diagnostic testing services, Mortara mentioned.
The corporate has accomplished case research with well being methods together with CommonSpirit Well being, Northwell Well being, Rush College Well being System and Sanford Well being.
Picture: franckreporter, Getty Photos
